Introduction
Nutraceutical, a hybrid term from 'nutrition' and 'pharmaceutical' coined by Stephen L. DeFelice in 1989, was defined as 'any substance that is a food or a part of food and provides medical or health benefits, including the prevention and treatment of disease' [1] . Later on, the concept of nutraceutical was modified as 'a product isolated or purified from foods that is generally sold in medicinal forms not usually associated with food' [2] . Nutraceuticals are now more specific to structurally and functionally diverse bioactive compounds that exert longtern medicinal or physiological benefits other than purely nutritional or direct pharmaceutical effects, which distinguishes them from functional foods and drugs. They can be derived from plants (e.g. phytochemicals, vitamins), from animals (e.g. polysaccharides), from microorganisms (e.g. poly amino acids) and from marine sources (e.g. glucosamine and chitosan). Nutraceuticals are widely used for their health-promoting or disease-preventing properties especially in preventing aging-associated diseases including oxidative stress, depression, inflammation, arthritis, osteoporosis, gastrointestinal diseases, cardiovascular diseases, diabetes and cancer [3] . The rising demands and interests in maintaining human wellness through diet have greatly promoted the growth of the nutraceutical market. According to Global Information Inc.' recent report, the global nutraceutical market was estimated to exceed $171.8 billion in 2014 and reach $241.1 billion by 2019, while the US market alone was about $75.9 billion [3] .
However, the expanding nutraceutical market can hardly be fulfilled by the productivity of conventional nutraceutical industries. Direct extraction strategies are limited by the availability and cost of raw materials, the quality control of supplies, and the low content and purity of nutraceuticals. Although chemical synthesis is an alternative approach, it is limited to producing simple biochemicals and is infeasible for complex biochemicals especially those that are chemically unfavorable [4] . To address these issues, microbial-based metabolic engineering is an appealing approach and has achieved great progress on production of value-added nutraceuticals in very recent years. The rapid elucidation of biosynthetic pathways for natural products and the genetic amenability of microorganisms have enabled the development of microbial hosts for production of various nutraceuticals. By further genetic manipulation of host cells and optimization of the culture conditions or fermentation processes, metabolic engineering makes it possible to scale up the production of nutraceuticals from simple carbon sources. As a matter of fact, certain commercial E. coli strains and food-grade S. cerevisiae have been industrially used as cell factories to produce natural products Generally Recognized As Safe (GRAS). This review covers recent advances in nutraceutical production via microbial-based metabolic engineering, including the well-studied phytochemicals, as well as prebiotics, polysaccaharides and poly amino acids.
Phytochemicals
Phytochemicals are a broad spectrum of plant-derived bioactive secondary metabolites that are commonly found in fruits, vegetables, beans and grains. They are involved in plant defenses against biotic or abiotic stresses, and also exhibit health-protecting or disease-preventing effects on humans [3] . Phytochemicals is a vast and very important repertoire for nutraceuticals, which include polyphenolic compounds (flavonoids, isoflavonoids, stilbenoids and curcuminoids), alkaloids, terpenoids (monoterpenes, diterpenes, tetraterpenes, polyterpenes, steroid saponins, lycopene and carotenoids) and their derived compounds.
Polyphenolic compounds
Amongst the phytochemicals, polyphenolic compounds have been used for decades as effective antioxidants and food ingredients in the nutraceutical industry. Polyphenolic scaffolds such as flavonoids and stilbenoids are derived from the phenylpropanoic pathway that extends from aromatic amino acids L-phenylalanine and L-tyrosine ( Figure 1 ) [5] . L-Phenylalanine and L-tyrosine are converted to pivotal intermediates cinnamic acid and p-coumaric acid via phenylalanine ammonia lyase (PAL) and tyrosine ammonia lyase (TAL), which are further converted to cinnamoyl-CoA and p-coumaroyl-CoA by 4-coumaroyl-CoA ligase (4CL), respectively. Then, three moles of malonyl-CoA condense with cinnamoyl-CoA or p-coumaroyl-CoA to construct the backbone flavanones, stilbenes or curcuminoids by type III polyketide synthases, such as chalcone synthase (CHS), curcuminoid synthase (CUS) or stilbene synthase (STS) [6] . With the action of tailoring enzymes such as hydroxylases, O-methyltransferases, glucosyltransferase, lipases and prenyltransferase, diverse polyphenolic compounds are generated [7] .
E. coli and S. cerevisiae have generally been developed as platform organisms for de novo or semi-de novo production of almost all kinds of polyphenolic compounds ( Table 1) . Some of the biggest advantages of E. coli include its fast growth and ease of genetic manipulation; for S. cerevisiae its Generally Regarded As Safe (GRAS) status and its ability to functionally express plant metabolic enzymes. In all cases, in order to achieve polyphenolic compound production in microbes, plant-originated enzymes are firstly overexpressed via either codon optimization or construction of enzyme chimeras that facilitate bacterial expression [8] . The first strategy is feeding precursors to the heterologous hosts to produce corresponding polyphenolic compounds. For example, supplementation with phenylalanine to E. coli expressing heterologous pathways produced chrysin (9.4 mg/L) or galangin (1.1 mg/L) while supplementation with tyrosine led to the production of apigenin (13 mg/L) or kaempferol (15.1 mg/L) (Table 1) [9] . This feeding approach is widely used when precursors are low or cannot be biosynthesized in microbes. Flavonoid glucosides like luteolin 4 0 -O-and 7 0 -O-glucosides were produced by feeding luteolin to E. coli expressing glycosyltransferases UGT71G1 [10] . By expressing glycosyltransferases with different substrate specificities, quercetin 3-O-glucoside, quercetin-3-O-glucuronide, quercetin 3-O-galactoside and quercetin-3-O-rhamnoside were respectively produced ( Table 1 ) [10] [11] [12] . The second approach is de novo biosynthesis of phenolic compounds from simple carbon sources like glucose and glycerol, which is more appealing for industrial applications. E. coli hosts can be easily metabolically engineered to overproduce L-phenylalanine and Ltyrosine from simple carbon sources. The intracellular concentration of malonyl-CoA, the extender unit for polyphenolic backbones, can be greatly enhanced in E. coli by overexpressing acetyl-CoA carboxylase (ACC) or genomescale metabolic optimization or by repressing malonyl-CoA consumption pathways using antisense RNA [13, 14 ]. E. coli has been successfully utilized for de novo biosynthesis of certain polyphenolic compounds such as pinocembrin, pinosylvin, sakuranetin and ponciretin [15] [16] [17] . Furthermore, substrate promiscuity of authentic or engineered enzymes has provided with new possibilities to produce novel or non-natural polyphenolic compounds [18 ,19] .
Alkaloids
Alkaloids are amino acid-derived nitrogenous compounds that have important therapeutic values, including anticancer and antimalarial effects [5] . For a long time, production of alkaloids was limited to plants because of their complex structure and long biosynthetic pathways. The three most well-known alkaloids are benzylisoquinoline alkaloids (BIAs) derived from tyrosine, monoterpene indole alkaloids (MIAs) derived from tryptophan and glucosinolates. In recent years, elucidation of many BIA biosynthetic pathways enabled the reconstruction of BIA pathways in both E. coli and S. cerevisiae [20 ,21,22] . (S)-reticuline, a branch-point intermediate for BIA, was biosynthesized from simple carbon sources with titer of 46.0 mg/L [20 ] . Bacteria consortia of E. coli producing (S)-reticuline and S. cerevisiae producing either monooxygenase CYP80G2 or the berberine bridge enzyme (BBE) yielded 7.2 mg/L magnoflorine and 8.3 mg/L scoulerine, respectively ( Figure 1 ) [23] . S. cerevisiae was also enabled to produce (R,S)-reticuline and was further engineered to generate scoulerine, tetrahydrocolumbamine and tetrahydroberberine from (S)-reticuline and salutaridine from (R)-reticuline [24] . However, metabolic engineering of MIA alkaloids in microbes is limited. Recently, de novo production of the MIA alkaloid strictosidine has been achieved in yeast by introducing 21 new genes and deleting 3 genes in the yeast genome (Table 1 ) [25 ] . Glucosinolates are sulfur-rich, amino acid-derived natural compounds. Tryptophan-derived indolylgluco-sinolate (IG) has recently been produced in S. cerevisiae by inserting eight plant genes into the genome, which represents a rare example of glucosinolate production in microbes ( Figure 1 ) [26 ] . Although plant platforms are more suitable for scalable alkaloid production, metabolic engineering in microbes has shown potential capability for cost-efficient production of these plant-derived compounds [7, 25 ].
Terpenoids
Terpenoids are present in green foods, soy plants and cereals, and serve as the largest class of phytonutrients with anti-inflammatory, anti-infectious and anti-cancer Examples of microbial-based production of phytochemicals from aromatic amino acids. Arrows represent the metabolic flux from primary shikimate pathway to target phytochemicals. Polyphenolic compounds are derived from phenylalanine or tyrosine, benzylisoquinoline alkaloids (BIA) are derived from tyrosine, monoterpene indole alkaloids (MIA) and indolylglucosinolate (IG) are derived from tryptophan.
properties [3, 7] . Terpenoids are isopentenyl pyrophosphate (IPP) or dimethylallyl pyrophosphate (DMAPP) derived compounds of diverse carbon skeletons, including monoterpenes (C 10 , e.g. menthol), sesquiterpenes (C 15 , e.g. artemisinin), diterpenes (C 20 , e.g. paclitaxel), triterpens (C 30 , e.g. steroids), tetraterpenes (C 40 , carotenoids) and polyterpenes [5] . Microbial production of terpenoids such as taxadiene (intermediate of anticancer drug paclitaxel) and artemisinic acid (precursor of antimalarial drug artemisinin) exemplified the advances and successes of metabolic engineering for production of value-added terpenoid pharmaceuticals. In nutraceutical industries, tetraterpene carotenoids such as b-carotene, lutein, lycopene, a-carotene and astaxanthin serve as natural food colorants and feed supplements [5] . Combinatorial carotenoid biosynthesis in heterologous non-carotenogenic hosts like E. coli and S. cerevisiae has been achieved for decades. Since then, metabolic engineering efforts have mainly focused on large-scale production of carotenoids. Strain optimization via systematic and combinatorial gene knockouts significantly increased lycopene production in E. coli [6] . Engineering central metabolic modules of E. coli to increase ATP and NADPH supplies improved b-carotene production to 2.1 g/L b-carotene with a yield of 60 mg/g DCW [27] . Lycopene derived zeaxanthin was biosynthesized and its production improved to 43.46 mg/L via protein fusion approaches for coordinating expression of lycopene b-cyclase gene crtY and b-carotene 3-hydroxylase gene crtZ [28] . A plasmid-free E. coli strain with the xanthophyll biosynthetic genes chromosomally integrated produced astaxanthin with a yield of 1.4 mg/g DCW [29] . Besides conventional carotenoids, discovery and production of new carotenoids with health-promoting benefits have also increased the pool of available carotenoids. Novel carotenoids such as 4-ketozeinoxanthin and the rare C 50 carotenoids sarcinaxanthin, decaprenoxanthin and sarprenoxanthin have been produced in lycopene-producing E. coli hosts [30, 31] . Recently, a non-natural purple carotenoid C 50 -astaxanthin was produced in E. coli using mutants of the first two pathway enzymes, farnesyl diphosphate synthase (FDS) and carotenoid synthase (CrtM), with shifted size-range substrate selectivities to enhance production of C 50 backbone while suppress non-target compounds [32 ] .
Prebiotics
A prebiotic is defined as 'a nonviable food component that confers a health benefit on the host associated with modulation of the microbiota' by The Food and Agriculture Organization of the United Nations (FAO) [33] . Prebiotics are non-digestible saccharide polymers that contain 3-10 monomeric sugar units (Figure 2) . The beneficial effects of prebiotics on humans lie in their modulation on diversity and metabolic activity of the gut microbiota, which may consequently have significant impact on the host immune system. Thus, prebiotics could be used to treat inflammatory diseases by boosting probiotics like Bifidobacteria or Lactobacillus species within the gut microbiota [34] . Representative prebiotics include inulin, fructo-oligosaccharides (FOS) and galacto-oligosaccharides (GOS). Inulin and inulin-type fructans, also known as soluble dietary fibers, could be produced by probiotic Lactobacillus gasseri strains [35] . GOS are lactose-derived galactose polymers with shorter
Microbial production of nutraceuticals Wang et al. 101 polymer chains. GOS could be produced by Kluyveromyces lactis with a titer of 177 g/L from 400 g/L lactose [36] . Expression of codon-optimized b-galactosidase from the hyperthermophile Sulfolobus solfataricus in Lactococcus lactis efficiently converted lactose to GOS [37] . 2 0 -Fucosyllactose (2 0 -FL) is one of the most abundant oligosaccharides in human milk and has been approved as nutritional additive in term infant and toddler formulas. By increasing the availability GDP-L-fucose and overexpression of fucosyltransferase, 2 0 -FL could be largely produced from lactose and glycerol in E. coli [38, 39 ].
Polysaccharides
Polysaccharides are sugar polymers of versatile structures that can be largely produced by several bacteria, yeast and fungi or extracted from plant and animal tissues ( Figure 2 ). Microbial polysaccharides have been recognized as a source for nutraceuticals owing to their healthbeneficial properties. Bacterial polysaccharides such as xanthan, gellan, dextrans and alginate can be commercialized via microbial production and purification [40] . Exopolysaccharides (EPS) are preferentially produced via metabolic engineering of Lactococcus and Streptococcus for their wide use in dairy products. Especially, bioactive fungal polysaccharides have demonstrated extensive immunostimulating, antitumor, antimicrobial, antioxidant, hypocholesterolaemic and hypoglycaemic benefits, thus indicating great potential in both nutraceutical and pharmaceutical applications [41] . Potential antitumor and antiviral polysaccharide scleroglucan is an extracellular glucan excreted by mycelia of Sclerotium rolfsii, whose yields could be enhanced via addition of L-lysine and uridine monophosphate (UMP) [41] . Instead of extraction from animal tissues, several animal polysaccharides like hyaluronic acid (HA), chondroitin and heparosan have also been produced by microbial hosts. Microbial production of hyaluronic acid has been achieved in various hosts including E. coli, Lactococcus lactis and Streptomyces albulus [42] [43] [44] . Medicinally important polysaccharides such as heparosan and chondroitin can be produced by engineered E. coli reaching a relatively high titer of 1.88 g/L and 2.4 g/L, respectively (Table 1 ) [45 ,46] .
Poly amino acids
Poly amino acids are synthesized in microorganisms from one or two type of amino acids by ribosomeindependent enzymatic processes that distinguish them from protein synthesis. Three kinds of poly amino acids, namely poly-g-glutamic acid (g-PGA), poly-e-L-lysine (e-PL) and multi-L-arginyl-poly(L-aspartic acid) (cyanophycin), are present in nature (Figure 2 ). g-PGA is a water-soluble and biodegradable polymer that can be used as a degradable biomaterial such as drug carriers or hydrogels. g-PGA can be largely produced (20-50 g/L) by Bacillus species when feeding L-glutamic acid. In order to achieve g-PGA production from glucose, optimization of co-cultivation of Corynebacterium glutamicum and Bacillus subtilis could maximally produce 32.8 g/L g-PGA [47] . Cyanophycin was produced from equimolar amounts of arginine and aspartic acid by cyanobacteria and some other chemotrophic bacteria (e.g. Acinetobacter calcoaceticus), which can be used as a precursor of dipeptides for nutritional and therapeutic applications. Overexpression of cyanophycin synthetase cphA from Synechocystis sp. PCC 6803 in E. coli achieved cyanophycin production with productivity of 120 mg/g CDW [48] . e-PL is a microbial-derived homo-poly amino acid that is synthesized by polymerization of lysine via e-PL synthetase (PLS). e-PL possesses antibacterial and anticancer activities and has been approved as food preservative or dietary agent in Japan and United States [49] . e-PL was produced by Streptomyces species such as Streptomyces albulus. Production of e-PL in Streptomyces sp. M-Z18 could reach 35.14 g/L when using glucose and glycerol as carbon sources [64] .
Conclusions
The last few decades have witnessed the remarkable progresses of nutraceuticals production via metabolic engineering of microbial-based platforms, which is in response to the great demands for value-added nutraceuticals to fortify humans against diseases. Metabolic engineering in microbes made possible not only the laboratory-scale preparation but also industrial-scale production of complex natural products such as carotenoids from simple carbon sources. Especially, with the elucidation of biosynthetic pathways and development of synthetic biology strategies, novel or more complicated valueadded compounds could be produced in microbes in a naturally developed manner. The amenability of genetic manipulation and tolerance of heterologous enzymes enabled microbes to produce diverse nutraceuticals via harnessing their native metabolic networks. One of the major limitations of microbial platform is the efficiency of plant or animal-derived enzymes that limit the productivity of the target compounds. While other non-microbial production platforms such as algae and plant-derived cell cultures have also been developed to produce natural or non-natural value-added nutraceuticals, there is little doubt that continuing advances in metabolic engineering and synthetic biology will allow the production of virtually any nutraceutical through a microbial host.
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